08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
OSHA recently announced its intention to remodel the online delivery of its general industry, constr...
Read More >
In a premises liability action, the duty a landowner owes depends on the status assigned to the pers...
Read More >
Congress recently passed the economic stimulus package referred to as the Coronavirus Aid, Relief, a...
Read More >
Most deals are approved, but the landscape is becoming increasingly complex, as more types of transa...
Read More >
For more than seven years now, policymakers and taxpayers have clamored for Congress to change the l...
Read More >
The UK Parliament’s Foreign Affairs Committee has issued a “call for evidence” as part of its ong...
Read More >